Investment in developers of cell and gene therapies has nosedived this year, a sharp drop-off that investors and analysts say reflect manufacturing and drug delivery challenges at a time when biotechnology companies with clear development paths are increasingly favored. So far this year, makers of cell and gene therapies have raised half of a billion dollars across 16 venture rounds, according to data from DealForma published by Nature. Even annualized, those numbers are well below the $8.2 billion in funding brought in by the 121 deals DealForma counted during the sector’s peak in 2021. Last year, cell and gene therapy developers raised $3.5 billion across 65 deals.
Read the full article: Cell and Gene Therapy Investment, Once Booming, Is Now in a Slump //
Source: https://www.biopharmadive.com/news/cell-gene-therapy-biotech-venture-investment-decline/725401/